Report LibraryAll Reports
Datamonitor Healthcare I&I: Opioid-Induced Constipation (OIC) Market Spotlight
November 05, 2018Opioids are increasingly used to reduce severe chronic and acute noncancerous pain, including spinal osteoarthritis, failed back surgery, and back pain. However, adverse gastrointestinal effects potentially reduce the clinical utility of opioids. Generally, between 40–95% of patients using opioids develop opioid-induced constipation (OIC). It is the most common side-effect, as tolerance does not arise over the long-term, in contrast to what is observed with other symptoms such as vomiting, sedation, and nausea. OIC can occur at any time after the initiation of opioid analgesics, and will negatively affect a patient’s quality of life, psychological wellbeing, work productivity, and daily activity.
This Datamonitor Healthcare report contains a Market Spotlight module.
|Disease Group Covered:||Gastroenterology (non inflammatory bowel disease)|